Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Biotech
AstraZeneca, Daiichi ADC fails to improve breast cancer survival
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Dato-DXd has again failed to improve overall survival in a phase 3 trial.
Nick Paul Taylor
Sep 23, 2024 7:23am
Merck, Daiichi ADC hits goal in phase 3 lung cancer study
Sep 17, 2024 7:13am
AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail
Sep 10, 2024 6:00am
Merck, Daiichi repeat early success in small cell lung cancer
Sep 9, 2024 10:27am
AZ outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC
Sep 8, 2024 12:22pm
Daiichi pays Merck $170M to form lung cancer T-cell engager pact
Aug 6, 2024 8:17am
